2seventy bio, Inc. - Common Stock TSVT 深 沪
已收盘 05-13 16:00:00 美东时间
5.00
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.00
- 总市值 2.66亿
- 52周最高 5.30
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.29
- 委 比 0.00%
- 总股本 5322.98万
- 历史最高 44.34
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.535
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多2seventy bio Completes Merger, Delists from Nasdaq
2seventy bio ( ($TSVT) ) just unveiled an update. On May 13, 2025, 2seventy bio...
2025-05-13 21:49
2seventy bio Q1 EPS $0.01 Beats $(0.12) Estimate, Sales $22.94M Beat $13.96M Estimate
2seventy bio (NASDAQ:TSVT) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.12) by 108.33 percent. This is a 101.23 percent increase over losses of $(0.81) per share from
2025-05-08 04:14
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BHLB, TSVT, RDFN on Behalf of Shareholders
NEW YORK, April 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/o...
2025-04-17 10:52
美股大行评级 | Tigress Financial：维持爱彼迎"买入"评级，目标价从195美元升至200美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107588488073326592.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持ProQR Therapeutics(PRQR)"买入"评级，目标价从10美元升至12美元</p> <p>• Oppenheimer：上调内克塔治疗(NKTR)评级至"跑
2025-03-17 10:10
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders
NEW YORK, March 12, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/o...
2025-03-13 07:13
美股牛股 | 禾赛暴涨逾50%！基因治疗公司TSVT暴涨76%
禾赛暴涨逾50%！公司据悉将向梅赛德斯供应激光雷达传感器；基因治疗公司TSVT暴涨76%，百时美施贵宝将以约2.86亿美元收购该公司
2025-03-12 19:20
一夜暴涨76%！蓝鸟生物分拆公司“嫁入”百时美施贵宝
转自：一度医药 2025年3月10日，百时美施贵宝（BMS）宣布将以每股5.00美元的全现金交易方式收购2seventy bio（TSVT.US），总股本价值...
2025-03-12 16:50
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
2025-03-12 11:01
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Shares of Paymentus Holdings, Inc. (NYSE:PAY) rose sharply in today's pre-marke...
2025-03-11 18:55
Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data
Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.
2025-02-07 20:50
